Differential regulation of mouse equilibrative nucleoside transporter 1 (mENT1) splice variants by protein kinase CK2

References

• Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 2004; 447: 735–743
   PubMed Web of Science ®Google Scholar
• Cass CE. Membrane transport of anticancer drugs and drug resistance. Pharmacological sciences: Perspectives for research and therapy in the late 1990s, AC Cuello, B Collier. Birkhauser Verlag, BaselSwitzerland 1995; 413–431
   Google Scholar
• Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099–3108
   PubMed Web of Science ®Google Scholar
• Choi DS, Handa M, Young H, Gordon AS, Diamond I, Messing RO. Genomic organization and expression of the mouse equilibrative, nitrobenzylthioinosine-sensitive nucleoside transporter 1 (ENT1) gene. Biochem Biophys Res Commun 2000; 277: 200–208
   PubMedGoogle Scholar
• Coe I, Zhang Y, McKenzie T, Naydenova Z. PKC regulation of the human equilibrative nucleoside transporter, hENT1. FEBS Lett 2002; 517: 201–205
   PubMed Web of Science ®Google Scholar
• Coe IR, Dohrman DP, Constantinescu A, Diamond I, Gordon AS. Activation of cyclic AMP-dependent protein kinase reverses tolerance of a nucleoside transporter to ethanol. J Pharmacol Exp Ther 1996; 276: 365–369
   PubMed Web of Science ®Google Scholar
• Damaraju VL, Damaraju S, Young JD, Baldwin SA, MacKey J, Sawyer MB, Cass CE. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 2003; 22: 7524–7536
   PubMed Web of Science ®Google Scholar
• Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 2001; 24: 31–55
   PubMed Web of Science ®Google Scholar
• Hammond JR. Comparative pharmacology of the nitrobenzylthioguanosine-sensitive and -resistant nucleoside transport mechanisms of Ehrlich ascites tumor cells. J Pharmacol Exp Ther 1991; 259: 799–807
   PubMed Web of Science ®Google Scholar
• Hammond JR. Interaction of a series of draflazine analogues with equilibrative nucleoside transporters: species differences and transporter subtype selectivity. Naunyn Schmiedebergs Arch Pharmacol 2000; 361: 373–382
   PubMedGoogle Scholar
• Hammond JR, Stolk M, Archer RG, McConnell K. Pharmacological analysis and molecular cloning of the canine equilibrative nucleoside transporter 1. Eur J Pharmacol 2004; 491: 9–19
   PubMedGoogle Scholar
• Handa M, Choi D, Caldeiro RM, Messing RO, Gordon AS, Diamond I I. Cloning of a novel isoform of the mouse NBMPR-sensitive equilibrative nucleoside transporter (ENT1) lacking a putative phosphorylation site. Gene 2001; 262: 301–307
   PubMed Web of Science ®Google Scholar
• Jarvis SM, Martin BW, Ng AS. 2-Chloroadenosine, a permeant for the nucleoside transporter. Biochem Pharmacol 1985; 34: 3237–3241
   PubMedGoogle Scholar
• Kiss A, Farah K, Kim J, Garriock RJ, Drysdale TA, Hammond JR. Molecular cloning and functional characterization of inhibitor- sensitive (mENT1) and inhibitor-resistant (mENT2) equilibrative nucleoside transporters from mouse brain. Biochem J 352 Pt 2000; 2: 363–372
   Google Scholar
• Kong W, Engel K, Wang J. Mammalian nucleoside transporters. Curr Drug Metab 2004; 5: 63–84
   PubMed Web of Science ®Google Scholar
• Pinna LA. Protein kinase CK2: A challenge to canons. J Cell Sci 2002; 115: 3873–3878
   PubMed Web of Science ®Google Scholar
• Ritzel MW, Ng AM, Yao SY, Graham K, Loewen SK, Smith KM, Hyde RJ, Karpinski E, Cass CE, Baldwin SA, Young JD. Recent molecular advances in studies of the concentrative Na + -dependent nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). Mol Membr Biol 2001; 18: 65–72
   PubMed Web of Science ®Google Scholar
• Sarno S, Reddy H, Meggio F, Ruzzene M, Davies SP, Donella-Deana A, Shugar D, Pinna LA. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 (‘casein kinase-2’). FEBS Lett 2001; 496: 44–48
   PubMed Web of Science ®Google Scholar
• Stolk M, Cooper E, Vilk G, Litchfield DW, Hammond JR. Subtype-specific regulation of equilibrative nucleoside transporters by protein kinase CK2. Biochem J 2005; 386: 281–289
   PubMedGoogle Scholar
• Van Belle H. Nucleoside transport inhibition: a therapeutic approach to cardioprotection via adenosine?. Cardiovasc Res 1993; 27: 68–76
   PubMedGoogle Scholar
• Ward JL, Sherali A, Mo ZP, Tse CM. Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. ENT2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine. J Biol Chem 2000; 275: 8375–8381
   PubMed Web of Science ®Google Scholar
• Zien P, Duncan JS, Skierski J, Bretner M, Litchfield DW, Shugar D. Tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) as selective inhibitors of protein kinase CK2: Evaluation of their effects on cells and different molecular forms of human CK2. Biochim Biophys Acta 2005; 1754: 271–280
   PubMedGoogle Scholar